Company news
Xenetic Biosciences, Inc. news in 2025
Xenetic Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
December 11, 2025
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
November 19, 2025
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
November 13, 2025
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
October 10, 2025
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
August 13, 2025
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
July 30, 2025
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
July 23, 2025
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
July 8, 2025
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreat...
July 7, 2025
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
May 14, 2025
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
April 9, 2025
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
March 26, 2025
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
March 19, 2025
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
March 13, 2025
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
February 27, 2025